Whole-body MRI vs bone scintigraphy in the staging of Ewing sarcoma of bone: a 12-year single-institution review

Kalus, Sarah; Saifuddin, Asif

doi:10.1007/s00330-019-06132-9

Cited by 27 publications

(18 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparative retrospective studies have corroborated the superiority of FDG-PET and WB-MRI over bone scintigraphy in detecting bone metastases in ES with the exception of skull vault lesions discerned by bone scinitigraphy [38][39][40]. In a 12-year retrospective review comprising 182 ES patients, Kalus et al reported a greater number of bone metastases were detected through staging with WB-MRI compared with bone scan, 24 and 16.9%, respectively [40].…”

Section: Fdg-pet/ct and Wb-mri Staging In Esmentioning

confidence: 93%

“…In a 12-year retrospective review comprising 182 ES patients, Kalus et al reported a greater number of bone metastases were detected through staging with WB-MRI compared with bone scan, 24 and 16.9%, respectively [40]. In 13 patients (18.3%) who had both modalities performed and bone metastases detected, 4 had bone metastases only identified on WB-MRI [40].…”

Section: Fdg-pet/ct and Wb-mri Staging In Esmentioning

confidence: 99%

“…Retrospective analyses largely conducted on the paediatric and TYA population have shown within their limits that FDG-PET/CT has excellent sensitivity for bone metastases and is equivalent to BMB sampling for localised disease (at the per patient level). The bone scan has lower sensitivity [23,40], thus if it is the only modality available for skeletal imaging, BMB could be considered in specific circumstances, such as for patients with oligometastatic disease being considered for radiation to all sites. In distinguishing localised from metastatic disease, including bone marrow involvement, the performance of a staging BMB does not add to the sensitivity accomplished with noninvasive modern-day functional imaging.…”

Section: Recommendationsmentioning

confidence: 99%

See 2 more Smart Citations

Is It Time to Call Time on Bone Marrow Biopsy for Staging Ewing Sarcoma (ES)?

Ingley

Wan

Vöö

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Primary malignant bone sarcomas are rare and Ewing sarcoma (ES), along with osteosarcoma, predominates in teenagers and young adults. The well-established multimodality treatment incorporates systemic chemotherapy with local control in the form of surgery, with or without radiation. The presence and extent of metastases at diagnosis remains the most important prognostic factor in determining patient outcome; patients with skeletal metastases or bone marrow infiltration having a significantly worse outcome than those with lung metastases alone. There is, however, no accepted staging algorithm for ES. Large cooperative groups and national guidelines continue to advocate bone marrow biopsy (BMB) for staging but functional imaging techniques, such as 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) with computerised tomography (CT) have been increasingly used for staging cancers and whole-body magnetic resonance imaging (WB-MRI) for staging skeletal metastases. This review outlines the current literature, from which we conclude that BMB is no longer required for the staging of ES as it does not influence the standard of care management. BMB may, however, provide prognostic information and insights into the biology of ES in selected patients on prospective clinical trials.

show abstract

Section: Fdg-pet/ct and Wb-mri Staging In Esmentioning

confidence: 93%

Section: Fdg-pet/ct and Wb-mri Staging In Esmentioning

confidence: 99%

Section: Recommendationsmentioning

confidence: 99%

See 1 more Smart Citation

Is It Time to Call Time on Bone Marrow Biopsy for Staging Ewing Sarcoma (ES)?

Ingley

Wan

Vöö

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…[95][96][97][98][99] WB-MRI appears comparable to FDG-PET/CT and superior to bone scintigraphy, without requiring ionising radiation. 88,100 In centers with access to these imaging modalities, it is possible to avoid an invasive bone marrow biopsy. Widespread acceptance for PET-CT or alternatively, WB-MRI as the standard for staging bone marrow will require prospective trials that incorporate large homogenous cohorts of patients with ES.…”

Section: Ewing Sarcomamentioning

confidence: 99%

“…MRI remains the gold standard to identify the intramedullary extent of primary bone tumors, including skip metastases. 100,123 Preoperative imaging however, is unfortunately not able to assess the response of tumors to neoadjuvant chemotherapy with sufficient reliability to influence surgical options. 124 Intraoperative imaging techniques, such as fluorescence using indocyanine green, offer the prospect of guiding surgeons towards improved surgical margins, but have yet to be proven in large scale clinical trials.…”

Section: New Surgical Techniquesmentioning

confidence: 99%

Current Approaches to Management of Bone Sarcoma in Adolescent and Young Adult (AYA) Patients

Ingley

Maleddu

Grange

et al. 2021

Preprint

View full text Add to dashboard Cite

Bone tumors are a group of histologically diverse diseases which occur across all ages. Two of the commonest, osteosarcoma (OS) and Ewing sarcoma (ES), are regarded as characteristic AYA cancers with an incidence peak in AYAs. They are curable for some but associated with unacceptably high rates of treatment failure and morbidity. The introduction of effective new therapeutics for bone sarcomas is slow, and to date, complex biology has been insufficiently characterized to allow more rapid therapeutic exploitation. This review focuses on current standards of care, recent advances that have or may soon change that standard of care and challenges to the expert clinical research community that we suggest must be met.

show abstract

The Role of Whole‐Body MRI in Pediatric Musculoskeletal Oncology: Current Concepts and Clinical Applications

Guimarães

Cruz

Ahlawat

et al. 2021

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Whole‐body magnetic resonance imaging (WB‐MRI) has gained importance in the field of musculoskeletal oncology over the last decades, consisting in a one‐stop imaging method that allows a wide coverage assessment of both bone and soft tissue involvement. WB‐MRI is valuable for diagnosis, staging, and follow‐up in many oncologic diseases and is especially advantageous for the pediatric population since it avoids redundant examinations and exposure to ionizing radiation in patients who often undergo long‐term surveillance. Its clinical application has been studied in many pediatric neoplasms, such as cancer predisposition syndromes, Langerhans cell histiocytosis, lymphoma, sarcomas, and neuroblastoma. The addition of diffusion‐weighted sequences allows functional evaluation of neoplastic lesions, which is helpful in the assessment of viable tumor and response to treatment after neoadjuvant or adjuvant therapy. WB‐MRI is an excellent alternative to fluorodeoxyglucose‐positron emission tomography/computed tomography in oncologic children, with comparable accuracy and the convenience of being radiation‐free, fast to perform, and available at a similar cost. The development of new techniques and protocols makes WB‐MRI increasingly faster, safer, and more accessible, and it is important for referring physicians and radiologists to recognize the role of this imaging method in pediatric oncology.Level of Evidence4Technical Efficacy Stage2

show abstract

Whole-body MRI vs bone scintigraphy in the staging of Ewing sarcoma of bone: a 12-year single-institution review

Cited by 27 publications

References 37 publications

Is It Time to Call Time on Bone Marrow Biopsy for Staging Ewing Sarcoma (ES)?

Is It Time to Call Time on Bone Marrow Biopsy for Staging Ewing Sarcoma (ES)?

Current Approaches to Management of Bone Sarcoma in Adolescent and Young Adult (AYA) Patients

The Role of Whole‐Body MRI in Pediatric Musculoskeletal Oncology: Current Concepts and Clinical Applications

Contact Info

Product

Resources

About